Trauma Informed Intervention to Support Engagement in HIV Care Among MSM (THRIVE+)

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05822206
Collaborator
The Fenway Institute (Other), Ryerson University (Other)
40
2
2
42.9
20
0.5

Study Details

Study Description

Brief Summary

This purpose of this project is to specify and provide an initial test of a 10 session, individual-based cognitive therapy intervention to address symptoms of PTSD and poor engagement in HIV care among men who have sex with men (MSM) with trauma histories

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CBT-TSC
  • Behavioral: Life Steps and Sexual Decision-Making
N/A

Detailed Description

The proposed intervention will incorporate the most current approaches to mediating trauma responses and stressors related to experiences of HIV stigma and homonegativity with cognitive-processing therapy, an empirically validated, cognitive-behavioral intervention for reducing negative consequences of traumatic stress. This intervention intends to improve uptake of HIV care in the prevention, engagement, and care cascade while also addressing the mental health needs of HIV-positive persons in a program of research that leads to outcomes in the short-term. If found to be efficacious, this intervention can also be scalable across clinical settings.

The study will be implemented at The Fenway Institute at Fenway Health (TFI) and at Ryerson University, Toronto, Canada and Drs. O'Cleirigh and Hart will assume the responsibility of coordinating the study across sites.

Randomization will be to the 10 session intervention or to two medication adherence/engagement in care sessions.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants are randomized into one of two conditions: treatment (Cognitive Behavioral Therapy for Trauma and Self-Care; CBT-TSC) or control. The CBT-TSC condition consists of 10 therapy sessions and 3 follow-up visits. The control condition consists of 2 therapy sessions and 3 follow-up visits. The first two therapy sessions, which are received by all participants regardless of condition, employ LifeSteps and sexual decision making techniques. The remaining eight therapy sessions, which only those in the CBT-TSC condition receive, address thoughts and behaviors associated with trauma distress and poor engagement in HIV care.Participants are randomized into one of two conditions: treatment (Cognitive Behavioral Therapy for Trauma and Self-Care; CBT-TSC) or control. The CBT-TSC condition consists of 10 therapy sessions and 3 follow-up visits. The control condition consists of 2 therapy sessions and 3 follow-up visits. The first two therapy sessions, which are received by all participants regardless of condition, employ LifeSteps and sexual decision making techniques. The remaining eight therapy sessions, which only those in the CBT-TSC condition receive, address thoughts and behaviors associated with trauma distress and poor engagement in HIV care.
Masking:
Single (Outcomes Assessor)
Masking Description:
Randomization is known to the study investigator, study clinician, project coordinator, and participant. The outcomes assessor is privy to randomization information.
Primary Purpose:
Treatment
Official Title:
Development of a Trauma Informed Intervention to Support Adaptive Engagement in Care Among MSM Living With HIV: Project THRIVE+
Actual Study Start Date :
Aug 3, 2016
Actual Primary Completion Date :
Dec 1, 2019
Actual Study Completion Date :
Mar 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment

Participants in the Treatment arm receive 2 therapy sessions on LifeSteps and sexual decision-making, as well at 8 sessions of Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC). Participants then participate in 3-, 6-, and 9-month follow-up assessments.

Behavioral: CBT-TSC
Cognitive Behavioral Therapy for Trauma and Self-Care

Behavioral: Life Steps and Sexual Decision-Making

Other: Control

Participants in the Control arm receive 2 therapy sessions on LifeSteps and sexual decision-making. Participants then participate in 3-, 6-, and 9-month follow-up assessments.

Behavioral: Life Steps and Sexual Decision-Making

Outcome Measures

Primary Outcome Measures

  1. ACTG Adherence Interview [up to 4 times over 9 months]

    HIV medication adherence is collected at all major time points (baseline, 3 month follow-up, 6 month follow-up, and 9 month follow-up) via self-report, using the AIDS Clinical Trials Group Adherence Interview. Participants are asked to give the number of doses they take of each of their HIV medications per day, and to note how many doses were missed at 4 time time points (yesterday, day before yesterday, 3 days ago, in the past 2 weeks).

Secondary Outcome Measures

  1. Davidson Trauma Scale [1 week]

    The Davidson Trauma Scale measures the frequency and severity of PTSD symptoms in the past week, and is conducted at each study visit (baseline, weekly visits, and all follow-up visits). Each item on the 17-item scale is scored 0-4 on frequency (0 = not at all; 4 = every day) and severity (0 = not at all distressing; 4 = extremely distressing), yielding a total between 0 and 136.

  2. Viral Load [baseline and 9 months]

    Most recent viral load is collected from each participant at baseline (first study visit) and at 9 month follow-up (final study visit) through medical record abstraction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • HIV-infected

  • is a man who has sex with men

  • has a history of trauma and is experiencing trauma-related distress (as operationalized by a score of >/= 20 on the Davidson Trauma Scale)

  • is sub-optimally engaged in HIV care (as operationalized by missing 1 or more HIV care appointments in the past 12 months, having a detectable viral load at most recent testing, or having poor adherence - </=80% - to HIV medications)

Exclusion Criteria:
  • has a significant mental health diagnosis that requires immediate treatment (e.g., acute major depression; panic disorder; any psychotic disorder)

  • unable to complete the informed consent process (e.g., substantial cognitive impairment, inadequate English language skills).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fenway Community Health Boston Massachusetts United States 02215
2 Ryerson University Toronto Ontario Canada M5B 1Y3

Sponsors and Collaborators

  • Massachusetts General Hospital
  • The Fenway Institute
  • Ryerson University

Investigators

  • Principal Investigator: Conall O'Cleirigh, PhD, Fenway Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Conall O'Cleirigh, Director of Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05822206
Other Study ID Numbers:
  • 931482-1
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Conall O'Cleirigh, Director of Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2023